You are here: Geisinger Medical
Laboratories > Test
Catalog
Geisinger Medical Laboratories Test Catalog
CA 19-9 |
||
Geisinger Epic Procedure Code: LAB1911
Geisinger Epic ID: 19446
|
||
SPECIMEN COLLECTION |
||
Specimen type: |
Serum (preferred) or plasma. | |
Preferred collection container: |
||
Alternate Collection Container: |
3 mL green/yellow-top (plasma separator) tube
|
|
Specimen required: |
1 mL serum or plasma; minimum 0.5 mL. | |
Special notes: |
Preferred specimen is serum in a 3.5 mL serum-separator tube. Plasma in a 3 mL plasma separator tube is also acceptable. | |
| SPECIMEN PROCESSING |
||
Specimen processing instructions: |
Allow serum to clot. Centrifuge to separate serum or plasma within 2 hours of collection. | |
Transport temperature: |
Refrigerated (preferred). Frozen specimen also acceptable. | |
Specimen stability: |
Room temperature: 5 days. Refrigerated: 14 days. Frozen: 3 months. | |
Rejection criteria: |
Stability limits exceeded. | |
TEST DETAILS |
||
Reference interval: |
< 35 U/mL. | |
Additional information: |
HAMA (Human Anti-Mouse Antibodies) interfere with this test. Patients who have been treated with mouse monoclonal antibodies should not be tested with this procedure. | |
CPT code(s): |
86301 | |
| Note: The billing party has sole responsibility for CPT coding. Any questions regarding coding should be directed to the payer being billed. The CPT codes provided by GML are based on AMA guidelines and are for informational purposes only. | ||
Test includes: |
Cancer antigen 19-9. | |
Methodology: |
Roche Electrochemiluminescence Immunoassay. Patient results determined by assays using different manufacturers or methods may not be comparable. |
|
Synonyms: |
CA1909, Cancer antigen 19-9
|
|
Clinical significance: |
A large percentage of patients wtih gastrointestinal tumors (such as pancreatic, liver, gastric, colorectal tumors) and some other malignancies have been shown to have elevated serum or plasma CA19-9 levels. CA19-9 levels may be useful for monitoring disease activity predicting relapse following treatment. CA19-9 should not be used as a screening test. | |
Doctoral Director(s:) |
Hoi-Ying Elsie Yu, PhD, DABCC, FADLM Sheng-Ying (Margaret) Lo, PhD, DABCC |
|
| Review Date: | 02/13/2024 | |